Reuters logo
BRIEF-Sanofi Ends Development Of Clostridium Difficile Vaccine
December 1, 2017 / 9:16 PM / in 10 days

BRIEF-Sanofi Ends Development Of Clostridium Difficile Vaccine

Dec 1 (Reuters) - Sanofi Sa:

* SANOFI ENDS DEVELOPMENT OF CLOSTRIDIUM DIFFICILE VACCINE

* SANOFI - IDMC FOR PHASE III CDIFFENSE CLINICAL TRIAL PROGRAM CONCLUDED THAT PROBABILITY THAT STUDY WILL MEET ITS PRIMARY OBJECTIVE IS LOW

* SANOFI - HAS DECIDED TO DISCONTINUE CLINICAL DEVELOPMENT OF ITS EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE

* SANOFI - SANOFI PASTEUR, VACCINES BUSINESS OF SANOFI RESPONSIBLE FOR PROGRAM, IS INFORMING INVESTIGATORS, REGULATORY AUTHORITIES & TRIAL ETHICS COMMITTEES

* SANOFI - INVESTIGATORS ARE NOTIFYING STUDY VOLUNTEERS OF DECISION TO STOP PROGRAM

* SANOFI - TO DISCONTINUE CLINICAL DEVELOPMENT OF EXPERIMENTAL CLOSTRIDIUM DIFFICILE VACCINE, TO FOCUS ON 6 VACCINE PROJECTS CURRENTLY IN DEVELOPMENT

* SANOFI - ‍DATA FROM ALL VACCINATED VOLUNTEERS WILL CONTINUE TO BE ANALYZED FOR MORE INFORMATION & SHARED WITH SCIENTIFIC COMMUNITY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below